Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...
Gladiator Metals Corp. (TSXV: GLAD) (OTCQB: GDTRF) (FSE: ZX7) ("Gladiator" or the "Company") is pleased to announce the receipt of additional assay results from its ongoing phase 2 drilling program at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback